Ignite Creation Date:
2024-05-05 @ 12:00 PM
Last Modification Date:
2024-10-26 @ 9:18 AM
Study NCT ID:
NCT00206063
Status:
TERMINATED
Last Update Posted:
2010-11-15
First Post:
2005-09-13
Brief Title:
Long Term Open Follow-up With H37695 vs Warfarin
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Study Overview
Official Title:
Long-Term Treatment With the Oral Direct Thrombin Inhibitor Ximelagatran Compared to Warfarin as Stroke Prophylaxis in Patients With Atrial Fibrillation A Long Term Follow-Up Study
Status:
TERMINATED
Status Verified Date:
2010-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Melagatranximelagatran was withdrawn from the market and clinical development in February 2006 in the interest of patient safety
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate tolerability of long-term treatment with ximelagatran compared to standard treatment with warfarin
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| D4004C00004 | None | None | None |